Short-term hormone therapy can improve outlook for men with early prostate cancer

October 05, 2005

Giving men with locally advanced prostate cancer 6 months of androgen deprivation therapy in addition to radiotherapy can substantially improve their outlook, concludes an article published online today (Thursday October 6, 2005) by THE LANCET ONCOLOGY.

Androgen deprivation therapy aims to lower concentrations of the male hormone testosterone in the body that can stimulate prostate cancer cells to grow. This type of hormone therapy is an established treatment for prostate cancer that has spread to other parts of the body. However, its role in treating localised prostate cancer is less clear.

Professor Jim Denham (Trans-Tasman Radiation Oncology Group, University of Newcastle, New South Wales, Australia) and colleagues recruited over 800 men with locally advanced prostate cancer from 19 centres in Australia and New Zealand. Patients were randomly assigned radiotherapy and either no testosterone suppression, 3 months' suppression or 6 months' suppression. When compared with men treated by radiotherapy alone, men treated with three months of goserelin and flutamide prior to and during radiotherapy had a 35% lower chance of relapse. For men treated with six months of hormone therapy prior to and during radiotherapy the risk of relapse was reduced by 44%.

Professor Denham states: "We have demonstrated a role for short-term testosterone suppression in the treatment of locally advanced prostate cancer...Our data suggest that 3 months' testosterone suppression reduced the risk of cancer returning in the prostate itself, but did not reduce the risk of spread of cancer to other parts of the body or increase cancer survival. However, 6 months testosterone suppression reduced the chances of cancer returning in the prostate even more. More importantly, it also reduced the chances of cancer spreading. Men treated this way, therefore, lived longer." (Quote by e-mail; does not appear in published paper)
Contact: Prof James Denham, University of Newcastle, Locked Bag 7, Hunter Region Mail Centre 2310, Australia. T) +61 2 4921 1174


Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to